Consistency in the performance of CDRH review divisions has improved in recent years, but FDA and lawmakers should closely monitor uniformity across the center and consider the need for reforms, according to the California Healthcare Institute.
CHI, an advocate for California’s biomedical companies, issued a report with help from The Boston Consulting Group on Oct. 23 assessing FDA's device review performance. It is based on data and information provided directly to the researchers by FDA as well as information from public databases. The analysis aligns with
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?